A¯atoxin B1 (AFB1) induced mutation of the p53 gene at codon 249 (p53mt249) is critical during the formation of hepatocellular carcinoma (HCC) following hepatitis B virus (HBV) infection. p53mt249 markedly increases insulin-like growth factor II (IGF-II) transcription largely from promoter 4, accumulating the fetal form of IGF-II. Modulation of the transcription factor binding to IGF-II P4 by wild-type p53 and p53mt249 was identi®ed. Wild-type p53 inhibited binding of transcription factors Sp1 and TBP on the P4 promoter, while p53mt249 enhanced the formation of transcriptional complexes through enhanced DNA-protein (Sp1 or TBP) and protein ± protein (Sp1 and TBP) interactions. p53mt249 stimulates transcription factor Sp1 phosphorylation which might be a cause of increased transcription factor binding on the P4 promoter while wild-type p53 does not. Transfection of hepatocytes with p53mt249 impaired induction of apoptosis by the HBV-X protein and TNF-a. Therefore, the blocking of apoptosis through enhanced production of IGF-II should provide a favorable opportunity for the selection of transformed hepatocytes. These results explain the molecular basis for the genesis of HCC by p53mt249 which was found to be induced by a potent mutagen, AFB1. Oncogene (2000) 19, 3717 ± 3726.
Introduction
Human IGF-II plays an important role in tumor progression in many tumors of dierent origins, including human hepatocellular carcinoma (HCC). In the liver, insulin-like growth factor II (IGF-II), originally called somatomedin A, is believed to function by autocrine or paracrine mechanisms of growth control in hepatocytes during malignant transformation (Daughaday and Rotwein, 1989) . The IGF-II transcripts synthesized at high levels in human and rodent fetal livers are overexpressed in certain embryonic tumors (Lamas et al., 1989) . Transcription of the human IGF-II gene is regulated by activation of four dierent promoters which act in a tissue-speci®c and development-dependent manner (Lamas et al., 1989; Holthuizen et al., 1990) . Promoter I becomes activated in adult liver tissue while promoters 2, 3 and 4 become activated in fetal liver tissue (Lamas et al., 1989; Holthuizen et al., 1990) . Under the control of these four dierent promoters, human IGF-II gene yields six kinds of mRNA species. In human adult liver tissue, a 5.3 kb mRNA species from promoter 1 is dominant, while two other species of mRNA, 6.0 kb and 4.8 kb, from promoter 3 and 4 are dominant in many fetal liver and non-hepatic tissues (Lamas et al., 1989) . Increasing levels of the fetal form of IGF-II transcripts have been reported in HCCs from woodchucks, rats and humans (Fu et al., 1998; Cariani et al., 1988) . Mutations in p53 are frequent in many types of human malignant tumors where these mutations are not random, located in the central DNA binding domain of p53. Among these mutations, missense mutations which comprise approximately 80% of all mutations with hot spots at codons 175, 248, 249 and 273, each encoding arginine, were found in many types of malignant tumors, suggesting that these mutant p53 proteins function either by abrogating the wild-type function or by gaining new oncogenic functions (Dittmer et al., 1993; Hsiao et al., 1994) . Major risk factors associated with HCC are dietary AFB1 exposure, chronic HBV and hepatitis C virus (HCV) infections and intake of alcoholic beverages. The incidence of HCCs by these factors varied upon geographical distribution with high incidence areas in Southeast Asia and sub-Saharan Africa and low incidence areas in Europe and North America. In high incidence areas, signi®cant epidemiologic associations with HBV infections and dietary AFB1 exposure have been demonstrated (Hsu et al., 1991; Bressac et al., 1991; Yeh et al., 1989; Greenblatt et al., 1994) . In vitro studies of AFB1 exposure is associated with a G:C?T:A mutation in the third base of codon 249, although animal models have shown neither codon 249 mutations nor a signi®cant level of other p53 mutations (Aguilar et al., 1993; Ozturk, 1991; Hulla et al., 1993) . In accordance with this, more than 50% of all HCCs from geographic regions with a high dietary AFB1 exposure contain p53 mutations in codon 249 (Hsu et al., 1991; Bressac et al., 1991) . Studies on the hepatocarcinogenic eects of HBV and/ or AFB1 on tree shrews (Tupaia glis) showed that the incidence of HCC was signi®cantly higher in animals both infected with HBV and exposed to AFB1 than in animals only infected with HBV or exposed to AFB1, suggesting that exposure to HBV and AFB1 may play a synergistic role in the development of HCC, supporting the idea of an etiological relationship between HBV and AFB1 (Yan et al., 1996; . A number of studies have demonstrated the modulation or abrogation of the wild-type p53 function by mutant p53s. On the other hand, mutant p53s that gain new functions are not well characterized. Studies have shown that mutant p53 expressed in cells lacking p53wt can result in enhanced tumorigenecity, metastatic potential and tissue invasiveness (Dittmer et al., 1993; Hsiao et al., 1994) . To determine whether the dominant negative eect or gain-of-funtion of p53mt249 is involved in IGF-II transcription, we measured the ability of transfected missense mutant p53 (249) in Hep3B (and Saos2) cells on IGF-II gene expression. We have shown that IGF-II P4 promoter is repressed by wild-type p53 but activated by tumorderived p53mt249. Experimental results on p53mt249 transfection showed an anti-apoptotic eect on HBV-X and TNF-a treated cell lines. This eect showed that activation of IGF-II transcription by p53 mutant not only increases IGF-II production as a mitogenic growth factor in tumor development but also acts as a surviving factor in apoptotic cell death by HBV infections (eventually selecting for neoplastic hepatocytes that have survived by synthesizing mitogenic growth factor IGF-II, during viral pathogenesis). These experimental results provide the molecular basis of the role of AFB1 induced p53 mutant during the formation of HCC in high incidence areas in the world.
Results

p53mt249 activate IGF-II transcription
We examined the molecular mechanisms of p53mt249 involvement in IGF-II transcription. Hep3B hepatoma cells, a p53 negative cell line derived from liver cancer, were used. Northern analysis was performed ( Figure  1a ) to examine p53mt249 activations of the endogeneous expression of IGF-II in Hep3B cells. p53wt, p53mt125, 248, 249 and antisense constructs of p53mt249 (p53mt249(AS)) were transfected into Hep3B cells. p53mt125 and 248 were used in order to examine whether the same mechanisms are involved in activating IGF-II as in the case of p53mt249.
The RD cell line which produces large amounts of endogeneous levels of IGF-II transcripts derived from promoter 3 (6.0 kb) and promoter 4 (4.8 kb) was used as a positive control (Figure 1a , lane 1). Northern analysis results showed that p53mt249 enhances IGF-II mRNA production from promoter 4 in Hep3B cells ( Figure 1a , lane 5) while p53wt represses IGF-II transcript production from both promoter 3 and 4 ( Figure 1a, lane 3) . The p53mt248 and 125 also enhances IGF-II mRNA production from promoter 4 in Hep3B cells (Figure 1a, lanes 4 and 7) . The same results were obtained when we used the HCV-core viral transactivator (submitted for publication). Since, p53mt249, 248, 125 and HCV-core showed the same results, the molecular mechanisms why promoter 3-derived transcripts become reduced and only promoter 4 derived transcripts become increased need to be clari®ed. In order to verify the speci®city of p53mt249 expression, (p53mt249(AS)) was co-transfected with p53mt249 in Hep3B cells (Figure 1a , lane 6). The expression of antisense p53mt249 reduced the 4.8 kb transcripts by p53mt249 expression from promoter 4 of IGF-II gene ( Figure 1a , lane 6). We performed cotransfection assays, using an IGF-II P4 promoter fused to a chloramphenicol acetyl transferase gene (pIG0-CAT), together with p53 wild-type (pCMV´p53wt) or p53mt249 expression vector (pCMV´p53mt249). As shown in Figure 1b , lanes 2 and 3, the wild-type p53 suppresses IGF-II P4 promoter activity twofold while p53mt249 activates this promoter about 3 ± 4-fold in the Hep3B cell line. We used dierent amounts of p53mt249 expression vectors (5 mg, 1 mg, 250 ng and 25 ng) for the activation of pIG0-CAT (2 mg) as shown in Figure  1b , lanes 3 ± 6. The per cent acetylation in CAT assay decreased as the amounts of p53mt249 expression vector decreased. When we cotransfected the p53mt249 and p53mt249 (AS) expression vectors, p53mt249 (AS) expression reduced the percentage of acetylation of p53mt249 on the pIG0-CAT construct ( Figure 1b , lane 7). The possible non-speci®c toxic eect on the cell growth by the antisense p53mt249 could be excluded since we used Hep3B cells which do not synthesize p53 and therefore do not depend on p53 expression for their growth. To determine whether the activation of IGF-II P4 promoter by p53mt249 is cell type speci®c, we cotransfected pIG0-CAT (10 mg) and pCMV´p53mt249 or the expression vector alone (pCMVneo) into Hep3B, HepG2 and PLC/PRF/5 cells. In all three cell lines the CAT activity was increased by p53mt249 more than the control expression vector (pCMVneo) indicating that p53mt249 transactivation of IGF-II P4 is not cell type speci®c (data not shown). To identify the p53mt249 response element of the IGF-II P4, we undertook a CAT assay using serially deleted promoter constructs (Hyun et al., 1993) . Data presented in Figure 1c indicate that the deletion construct pIG8 did not show any transactivation by p53mt249 while pIG7 did show transactivation. These results suggest that the sequences between 736 and 758 show p53mt249 responsiveness in the IGF-II P4 promoter. These sequences contained two Sp binding sites (-GGGTGG-) which have been identi®ed as RCE (Rb controlling element) and are important for HBV transactivator-X transactivation (Kim et al., 1992; Lee et al., 1998) . To examine the role of the Sp1 binding sites in p53mt249 mediated transcriptional regulation, both Sp1 binding sites were inactivated by changing the three internal base pairs of each site (Figure 1d, m3 ). Since both of the Sp1 binding sequences (GGGTGG) showed variations of the Sp1 consensus binding sequences (GGGCGG) a single T (m1, m2) and both Ts (m4) of the variant Sp1 sites were changed into C, in order to test the ability of the Sp1 consensus binding (GGGCGG) sequences to confer p53mt249 mediated transcriptional regulation (Figure 1d ). The eect of p53mt249 on the Sp1 binding site mutants was examined by co-transfection of the plasmid into Hep3B cells with and without p53mt249 expression vector (Figure 1d ). Mutant construct m1, m2 and m4 activities were induced 7 ± 8-fold by Sp1, whereas m3 was induced only 1.2-fold. Thus, the change of GGGTGG to the consensus Sp1 binding site GGGCGG had no eect on the ability of Sp1 to activate transcription, whereas inactivation of both Sp1 sites abolished Sp1 activation. These results suggest that p53mt249 can stimulate transcription of the IGF-II P4 promoter through the Sp1 binding sites. The same results were obtained when using the p53mt125 and 248 which implies the same mechanisms might be involved in activating the IGF-II promoter 4 (data not shown).
Gel retardation analysis of the IGF-II promoter 4 region
The pIG7 sequences of IGF-II P4 which contain two Sp1 binding sites and TATA-like sequences with two transcription initiation sites were described previously (Hyun et al., 1993) (Figure 2a) . In order to check whether p53wt, p53mt249 and TBP bind to the pIG7 fragment of IGF-II P4, 32 P-labeled pIG7 fragment (736*758) and TATA-like sequence (711*+3) of pIG7 were used for a gel retardation experiment using recombinant puri®ed p53wt, p53mt249 and TBP. Baculovirus expressed and puri®ed p53wt (20 ng) bind directly to the pIG7 fragment (736*758) and p53 consensus sequences (5'-GGACATGCCCGGG-CATGTCC-3') ( Figure 2b, lanes 1 and 3) . Though there was no p53 binding consensus sequence on pIG7, wild-type p53 bound to pIG7 fragment. Recombinant puri®ed Sp1 (2 fpu; Promega) was used as a positive control as described (21) (Figure 2b , lane 2). Baculovirus expressed and puri®ed p53mt249 also bound directly to pIG7 (Figure 2c , lane 1) while it does not bind to the p53 consensus binding site (lane 3). Baculovirus puri®ed p53wt (20 ng) was used as a positive control (lane 2). Gel retardation assay was performed using 32 P-labeled TBP consensus sequence (TATA) and the TATA-like sequence of (CATAA) pIG7. Puri®ed TBP bound to both TATA-like sequence and TBP consensus sequences ( Figure 2d , lanes 2 and 5) while Hep3B nuclear extracts formed high molecular weight protein/DNA complexes on both probes (Figure 2d , lanes 3 and 6). Unlabeled TBP consensus sequence (TATA) and TATA-like sequence (CATAA) of pIG7 were used as competitors in this experiment ( Figure 2d , lanes 1 and 4). These experimental results clearly show that Sp1, wild and mutant type p53 (p53mt249) bind to IGF-II P4 and TBP binds to the TATA-like sequence of IGF-II P4.
Modulation of transcription factor binding to IGF-II P4 by p53 wild-type and p53mt249
To characterize the functional importance of the interactions between Sp1 and p53 wild and mutant type, we analysed the synergistic eect of these transcription factors in the Schneider SL2 cell line that lacks proteins that are related to the mammalian Sp1 transcription factor. SL2 cells transfected with increasing amounts of Sp1 expression vector (pSp1; 1*10 mg) and 3 mg of p53mt249 expression vector together with 3 mg of IGF-II P4-CAT reporter plasmid (*) resulted in a signi®cant stimulation of CAT expression from the IGF-II P4 promoter ( These results clearly show that Sp1 and p53mt249 synergize in activating IGF-II P4. These synergistic eects are dependent on the Sp1 binding site since pIG8 which lacks the Sp1 binding site, failed to transactivate synergistically (data not shown). Since p53wt and p53mt249 as well as Sp1 bind to pIG7 of IGF-II P4, we checked whether p53 wild-type or mutant type aect the Sp1 binding to pIG7 (which eventually leads to the regulation of IGF-II transcription). . These experimental results show that wild-type p53 inhibits Sp1 from binding to its Sp1 binding site on IGF-II P4. Since our experimental results showed that baculovirus puri®ed p53mt249 binds to pIG7, we checked whether p53mt249 inhibits the Sp1 binding to pIG7. Figure 3b ± II, show that unlike wildtype p53, p53mt249 does not inhibit Sp1 binding to its Sp1 binding sites on IGF-II P4. Since a number of transcription factors are thought to bind to the region of pIG7 (736*758) within the IGF-II P4 promoter, activation of the promoter might be due to p53mt249 activation with the binding of such factors to the DNA sequence (pIG7). Such a mechanism has been reported to explain the repression of the c-myc promoter by p53 (Friend, 1994; Perrem et al., 1995) . To investigate this possibility, the Sp1 binding sequence and TATA-like sequence on pIG7 and TBP consensus sequences were Figure  3c ± II, lanes 5 and 9). These data imply that p53wt in some way prevents the formation of protein/DNA complexes while p53mt249 activates the formation of protein/DNA complexes. Our experimental result using p53wt also con®rms the previous report that mouse p53wt can also prevent the formation of a TBP/DNA complex (Perrem et al., 1995) . In order to verify whether other p53 mutants (p53mt125 and 248) also showed the increase of Sp1 and TBP binding on pIG7 and TATA consensus sequences, gel retardation experiments were performed. The same results ( Figure  3c 
Analysis of protein ± protein interactions and protein modifications on IGF-II P4
Since both Sp1 and p53 binding sites exist on pIG7 as shown in Figure 2 , we were interested whether these two transcription factors interact with each other. p53wt expression vector or p53mt249 expression vector were co-transfected with Sp1 expression vector into Schneider SL2 cells and then immunoprecipitated with anti-Sp1 antibody and protein A-sepharose. The precipitated immune complexes were immunoblotted with anti-p53 antibody (Figure 4a ± I) . The results shown in Figure 4 ± I illustrate that p53 wild-type binds with Sp1 (lane 3) while p53 mutant type does not bind with Sp1 in vivo (lane 2). The control, which was transfected with c-jun expression vector instead of p53wt, does not show any complex formations (lane 1). For the positive control, Schneider SL2 extract transfected with p53wt expression vector was immunoblotted with p53 antibody (lane 4). The same experiment using p53 antibody for immunoprecipitation and Sp1 antibody for immunoblotting was performed. The same results as in Figure 4a ± I appeared and it also showed that p53wt binds with Sp1 while p53mt249 does not (data not shown). These Nuclear extracts from Hep3B, p53wt and p53mt249 (or 125, 248) transfected Hep3B cells were incubated with Sp1 binding sequences (5'-GAGAGGGGTGGGGGGTAGGGTGGAGC-3') of pIG7. Speci®c Sp1/DNA complex was resolved on 4% polyacrylamide gel. II. p53mt125, 248 and 249 activates protein/DNA complex formation on TATA consensus sequence and the TATA-like sequence on pIG7. Nuclear extracts from Hep3B, p53wt and p53mt125, 248 and 249 transfected Hep3B cells were incubated with the 32 P-labeled TBP consensus sequence and Hep3B, p53wt and p53mt249 transfected Hep3B cells were incubated with the CATAAA sequence of pIG7. Speci®c TBP/DNA complex was resolved on 6% polyacrylamide gel results suggest the possibility of an interaction of Sp1 with wild-type p53 as a means of controlling its transcriptional activity. By using a Far-Western blot experiment, indirect interactions of p53 and Sp1 has been suggested, possibly mediated through other proteins (Shivakumar and Das, 1996) . Since we used the immune complexes from whole extracts, we can not rule out that other adaptor-like proteins could be involved in p53 and Sp1 interactions. In order to con®rm whether p53wt or p53mt249 expression aects the assembly of TBP and Sp1 into a transcription complex, Hep3B cells were transfected with p53wt or p53mt249 expression vector and immunoprecipitated with TBP antibody and then immunoblotted with Sp1 antibody. The results in Figure 4a ± II show that p53mt249 induced strong interactions of TBP and Sp1 (lane 1), while p53wt does not induce any interactions of TBP and Sp1 (lane 2). The c-myc transfected Hep3B cells instead of p53wt or p53mt249 were used as negative controls (lane 4). These results also suggest that p53mt249 induced interactions between TBP and Sp1 could be a mechanism of enhancing transcriptional activity of IGF-II. For the positive control, Schneider SL2 extracts transfected with Sp1 expression vector (pSp1) and immunoblotted with anti-Sp1 antibody were used. Since Sp1 expression vector contains a partial sequence of Sp1 (aa 145*393), the band appeared to be smaller than normal Sp1 (lane 3). Since p53mt249 induced Sp1 binding to pIG7 in Hep3B cells, we investigated whether p53mt249 aected Sp1 phosphorylation, which might be a cause of the increase of Sp1 binding to pIG7 Sp1 binding DNA sequences as described . Schneider cells which lack Sp1 were transfected with Sp1 expression vector (pSp1) and p53mt249 expression vector (pCMV´p53mt249) or p53wt expression vector (pCMV´p53wt) and in vivo labeled with 4) . These results clearly show that p53mt249 protein stimulates Sp1 phosphorylation, in vivo. Since p53 kinase activity has not been identi®ed, it is more likely that p53mt249 activated kinase, present in the SL2 cells, is responsible for Sp1 phosphorylations.
p53mt249 blocks HBV-X and TNF-a mediated apoptosis
The majority of HCC, derived from mammalian hepadnavirus infection, express growth factors, particularly IGF-II. IGF-II can function as a surviving factor in the development of virus-induced hepatoma by preventing programmed cell death in hepatoma cells exposed to deregulated N-myc expression (Ueda and Ganem, 1996; Yang et al., 1996) . Apoptosis and an increase in the level of TNF-a have been observed in HBV infected cells and the HBV-X protein have been known to sensitize cells to apoptotic killing by TNF-a (Su and Schneider, 1997) . Treatment of cells with mitogenic growth factor IGF-II by hepadnavirus induced tumors, showed impaired induction of apoptosis by HBV-X and TNF-a. To determine whether mutant type p53 induced IGF-II could suppress apoptotic killing induced by HBV-X and TNF-a, we ®rst checked whether Chang liver cells were susceptible to apoptotic killing by HBV-X and TNF-a (Figure 5d ) or HBV-X, TNF-a and p53wt (Figure 5f ). In condensed, Hoechst-stained nuclei, indications of apoptosis were evident on both treated cells (Figure  5d,f) . Addition of IGF-II or transfection with p53mt249 of these cells showed blockage of the cell killing by TNF-a and HBV-X (Figure 5e,g ). These results clearly showed that p53mt249 induced IGF-II could suppress apoptotic killing induced by HBV-X and TNF-a. For the control, TNF-a treated (Figure  5a ), HBV transfected (Figure 5b) or HBV transfected and IGF-II treated (Figure 5c ) Chang liver cells which do not show apoptosis after being stained with Hoechst 33258 were used. These experimental eects showed that p53mt249 activated IGF-II not only act as a mitogenic growth factor in tumor development, but also acts as a surviving factor in apoptotic cells induced by TNF-a and HBV-infection. Therefore the blocking of apoptosis through enhanced production of IGF-II should provide a favorable opportunity for the selection of transformed hepatocytes during the formation of HCC.
Discussion
A mutational hot spot, at codon 249 of p53 gene was found in HCC in individuals from AFB1 high risk regions (South Africa and Quidong Province, China). It has been shown that G to T mutations at the third base condon 249 occur in persons with HCC who have been exposed to HBV and high levels of AFB1, but not in those who have been exposed to HBV or HCV in the absence of AFB1. This strongly suggested that the codon 249 mutation of p53 in HCC is linked to HBV infection and AFB1 exposure. The molecular mechanisms of AFB1 induced p53 codon 249 mutant involvement in activation of IGF-II expression during the formation of HCC have been described elsewhere in this paper. The protein product of the normal p53 gene product binds to the DNA, p53 CON element (5'-GGACATGCCCGGG-CATGTCC-3'), thereby activating transcription from adjacent promoters (Funk et al., 1992) . In contrast to a previous report that all p53 mutants fail to bind to the p53CON, a p53 binding element, Zhang et al. (1998) reported that two p53 mutants (mt143Ala, mt273His) retained both p53CON binding and transcriptional activation functions while p53mt175His bound to the p53CON but did not activate transcription. Our experimental results showed that the pIG7 fragment of IGF-II promoter does not contain p53CON element, though p53 wild-type as well as p53mt249 protein bind to the fragment (Figure 2 ). Our experimental results agree well with Zhang's results where they showed direct binding of p53 to the P4 promoter despite the lack of p53 consensus binding site (Zhang et al., 1998) . Though p53mt249 did bind to pIG7 fragment, it did not bind to p53CON sequences (Figure 2 ). Since both p53 wild-type and p53mt249 bind to the pIG7 fragment, the activation or repression of IGF-II P4 might depend on the protein ± protein interactions on the promoters or degree of induction of transcription factor binding to the promoter region as shown in Figures 3 and 4 . In this report, we showed that p53mt249 synergized with Sp1 in transcriptional activation of IGF-II P4, enhanced the formation of Sp1/TBP interactions and their binding to the promoter and does not interfere with Sp1 binding to its binding sequence on pIG7 while p53 wild-type showed the opposite eect. These results could suggest that the DNA binding and transcriptional activation function of p53 mutants in tumor cells are dependent on the speci®c missense mutations acquired in the p53 gene and the target sequences of the p53 in the genome. Among the frequently mutated residues of p53 protein, six hot spots are known. These hot spots are p53mt175, 245, 248, 249, 273 and 282. Structural analysis of p53 mutants revealed that two mutants, mt248Arg and mt273Arg, make direct contact with DNA, while the remaining four hot spot residues appear to play a critical role in stabilizing the structure of the DNA binding surface of p53 (Friend, 1994) . p53mt249 (Arg) occurs in the L3 loop (residue 236*251) of p53, adjacent to the minor groove contact (Arg248) and it is surrounded by portions of L2 (residue 163*195) and L3 loops and the C-terminal end of the S3 strand (residue 141*146) from the a sandwich (Friend, 1994) . Since p53mt249 binds and activates IGF-II promoter 4, we assume therefore, that this mutation does not create major structural/conformational changes though the mutation residue (Arg249) is located adjacent to the minor groove contact (Arg248) of the consensus DNA sequence. Though p53mt125 and 248 showed the same experimental results as in the case of p53mt249 in activating IGF-II promoter 4, the eects of other p53 DNA-binding mutants including hot spot mutants (p53mt175, 245, 273 and 282) on IGF-II promoter 4 need to be veri®ed. The HBV-X protein sensitizes cells to apoptotic killing by TNF-a. Since treatment of IGF-II or p53mt249 transfection blocks the apoptotic eect of HBV-X and TNF-a, mitogenic growth factor IGF-II, activated by p53mt249, funtions as a surviving factor in Figure 5 Eect of p53mt249 treatment on HBV-X and TNF-a mediated apoptosis. p53mt249 expression blocks HBV-X sensitization of cells to TNF-a mediated apoptosis. Cells were cotransfected with HBV-X expression vector (pCMV´X) and p53wt or p53mt249 expression vector. These cells were harvested by trypsinization and 100 ml of cell suspension (2.0610 6 cells/ml) were put on coverslips and incubated. After 24 h, cells were treated with either 2.0 ng/ml TNF-a (Calbiochem.), 100 ng/ml IGF-II (Calbiochem.) or both for 16 h. Cells were ®xed with methanol/acetic acid (3:1), stained with 1 mg/ml Hoechst 33258 for 10 min. Stained cells were observed under Zeiss Jenalumā uorescence microscope. For positive control, HBV-X and TNF-a treated cells were used. For negative control, Chang liver cells treated with HBV-X or TNF-a alone or treated with 100 ng/ml IGF-II for 16 h were used impairing induction of apoptosis by HBV-X and TNF-a. Some mitogenic growth factors including PDGF, IL-3 and IGF-II promote cell survival during development and diseases such as cancer (Luis et al., 1997) . N-myc induced apoptosis in hepatocytes could be blocked by IGF-II which might be a surviving factor in the development of virus induced hepatoma . In the case of IL-3, Akt, a surviving promoting serine/threonine protein kinase is activated in PI-3 kinase dependent manner, which eventually phosphorylates BAD leading to BCl-2 functions as an anti-apoptotic factor (Sandeep et al., 1997) . Since p53mt249 activated IGF-II functions as a surviving factor in TNF-a and HBV-X treated hepatocytes, whether the molecular mechanisms of IGF-II functions as a surviving factor in blocking apoptosis are under investigation in our lab. Similar to our previous data on HBV-X activations of IGF-IR (Kim et al., 1996) , p53mt249 also activates IGF-IR transcription and increased the number of IGF-IR (submitted for publication). These results clearly indicate that increase of functionally active IGF-IR by p53mt249, together with the activation of IGF-II expression resulted in an increased paracrine or autocrine reactions of IGF-II and IGF-IR which eventually leads to antiapoptotic phenomena of the hepatoma cells. Involvement of mutant p53s in human cancer may result from their gain of new function or from the trans-dominant eect in which activity of the wild-type p53 is abrogated by complex formation. However, their biochemical functions in cancer cells remain largely unknown at present. It was recently reported that a common class of p53 missense mutations (p53 relaxed spindle checkpoint allele) exhibit a dominant gain of function activity that generate genomic instability which does not require the transcriptional activation function of p53 (Gualberto et al., 1998) . In this paper, we have shown that p53mt249 is involved in the transcriptional activation of P4 of the IGF-II gene through enhancement of the formation of Sp1/TBP interaction and their binding to the promoter, probably triggered by phosphorylation, in the case of Sp1. This function was not observed with the wild-type p53. Thus, the mechanisms involved in the activation of IGF-II transcription by p53mt249 and the downstream negative eect on apoptosis oer, for the ®rst time, an understanding of the molecular basis of the development of HCC in the AFB1 exposed population in the world.
Materials and methods
Cell culture, DNA transfection and CAT assays Human hepatoma cells, Hep3B, PLC/PRF/5, and HepG2 were grown in minimal essential medium supplemented with 10% fetal bovine serum. The rhabdomyosarcoma cell line (RD), an RMA cell line with an arginine to tryptophan mutation at codon 248 of p53 and expressing a high level of p3 and p4 promoter driven fetal form IGF-II transcripts, obtained from American Type Culture Collection (ATCC) were grown in a minimal essential medium supplemented with 10% fetal bovine serum. Transfections were carried out by the CaPO4 precipitation method (Luse and Roeder, 1980) . The CaPO 4 -DNA coprecipitate was established by overnight incubation. After glycerol shock the cells were further incubated for 48 h in a complete medium. The cells were then harvested and extracts were assayed for CAT activity according to the method of Gorman (Gorman et al., 1982) .
The Drosophila Schneider cells were maintained in Dulbecco's modi®ed Eagle's medium plus 10% fetal bovine serum. Drosophila Schneider cells were transfected by the calcium phosphate coprecipitation method using 100 ng of a control plasmid pSp1-0, or 100 ng of the Sp1 expression plasmid pSp1. Plasmid pSp1-0 and pSp1 contain the Drosophila actin promoter and polyadenylation signal. Transfection was carried out by the CaPO4 precipitation method (Luse and Roeder, 1980) . Quantitative results were calculated by excising spots corresponding to nonacetylated and acetylated forms from the TLC plates, which were then counted in a liquid scintillation spectrophotometer (Beckman Co., USA). The amount of apoptotic cells was determined by counting the fraction of cells stained with Hoechst 33258. Results represent the average from three independent experiments.
Plasmids and DNA
Adr subtype HBV DNA was isolated from HBV infected Korean patients (Kim and Kang, 1984) . The intact X gene was prepared from the pHBV315-dimer plasmid which has two copies of HBV DNA cloned into the BamH1 site of pBR322. The 540 bp NruI-BstEII fragment, which contains the fourth promoter region of the human IGF-II gene, was subcloned into pGEM4-SV0CAT (Promega, WI, USA) and was designated pIG0 (Hyun et al., 1993) . The deletion mutant series of the fourth promoter of the human IGF-II gene was constructed by PCR ampli®cation using oligonucleotides designed to generate ends with HindIII and XbaI restriction sites. The PCR product was then cloned into pGEM-SV0CAT, which was cut with the same enzymes and puri®ed in two sequential CsCl centrifugation steps as described (Hyun et al., 1993) . The wild-type and the mutant human p53 constructs p53-125A, p53-175H, p53-248W, p53-249T, p53-273H were provided by Dr Bert Vogelstein. For the p53mt249 anti-sense expression vector, the full-length human p53mt249 cDNA clone was subcloned in the pCMVneo expression vector in an anti-sense orientation and designated as p53mt249 (AS).
EMSA
Recombinant puri®ed Sp1, p53wt, p53mt249 and TBP (TATA-binding protein which is essential for transcription initiation) binding to each probe were done using buer containing 20 mM HEPES (pH 7.9), 1 mM MgCl 2 , 4% Ficoll, 0.5 mM DTT, 50 mM KCl and 2 mg poly dIdC. The recombinant Sp1 was purchased from Santa Cruz Biotechnoloy Co., USA and TBP from Promega Co., USA. The p53wt and p53mt249 proteins were expressed and puri®ed by using a baculovirus expression system as described (O'Reilly et al., 1992) . Recombinant puri®ed Sp1 or nuclear extracts from Hep3B cells transfected with p53wt or p53mt249 expression vector were incubated with Sp1 binding sequence (5'-GAGAGGGGTGGGGGGTAGGGTGGAGC-3') of pIG7. Speci®c Sp1/DNA complex was resolved on 4% PAGE. Baculovirus puri®ed p53wt and p53mt249 were incubated with pIG7 fragment (736*758) of pIGF-II P4. p53wt/ mt249-DNA complex was resolved on 4% PAGE. Recombinant TBP was used to bind to TBP-consensus sequence (5'-GCAGGCATATAAAATAGGTAGGA-3') and TATA sequence (5'-CACACATAAAAGCTG-3') of pIG7. TBP/DNA complex was resolved on 6% PAGE.
Immunoblot analysis
To detect the protein interactions by p53 wild-type and mutant type, p53wt expression vector (pCMV´p53wt) or p53mt249 expression vector (pCMV´p53mt249) were transfected into Schneider SL2 cells. The transfected SL2 cells were washed with PBS and harvested by scraping after 1 min incubation in TNE buer (50 mM Tris-HCl (pH 7.5), 1 mM EDTA and 0.15 M NaCl). Cells were pelleted and resuspended in 0.25 M Tris-HCl (pH 7.5) and disrupted by three cycles of freezing in liquid nitrogen and thawing at 378C. Protein concentration was determined with a Bio-Rad protein assay kit.
The whole cell extracts thus puri®ed were incubated with anti-Sp1 antibody (PEP2, Santa Cruz Co., CA, USA.) and precipitated with protein A-sepharose (Sigma, St. Louis, MO, USA). Precipitated immune complex was run on 11% SDSpolyacrylamide gel then transferred on to nitrocellulose paper. The transferred nitrocellulose paper was subjected to immunoblotting using anti-p53 antibody (pAb421, Santa Cruz Co., CA, USA) and then anti-mouse IgG conjugated with alkaline phosphatase. Color was developed by alkaline phosphatase substrate, nitro blue tetrazolium (NBT). For the Sp1 and TBP interaction, 5 mg of p53wt or p53mt249 expression vector were co-transfected into Hep3B cells. Immunoprecipitation was done with anti-TBP (9SI-1; Santa Cruz Co., CA, USA) antibody and protein A-sepharose (Sigma Co.). Precipitated immune complex was run on 11% SDS-polyacrylamide gel then transferred onto nitrocellulose paper. The transferred nitrocellulose paper was subjected to immunoblotting using anti-Sp1 antibody (PEP-2, Santa Cruz Co., CA, USA) and then goat anti-mouse IgG conjugated with alkaline phosphatase. Color was developed by alkaline phosphatase substrate, NBT.
In vivo and in vitro phosphorylation of Sp1
Sp1 transfected or pSp1, p53wt or p53mt249 (or 125, 248) double transfected Schneider cells were incubated with 1 mCi/ml 32 P-orthophosphate in phosphate free media for 1 h. After harvesting, the collected cells were lyzed and radiolabeled Sp1 were immunoprecipitated with polyclonal Sp1 antibody (Santa Cruz Co., CA, USA) and resolved by 8% SDS ± PAGE. Phosphorylated Sp1 was indicated by pSp1. For immunoblotting analysis of p53mt249 transfected cells on Sp1 protein levels, 100 mg of nuclear extracts from pSp1 transfected or pSp1, p53wt or p53mt249 double transfected Schneider cells were dephosphorylated using calf intestine alkaline phosphatase (1 unit/50 mg protein, BM Co.) or untreated. CIAP treated or untreated unclear extracts were immunoblotted using polyclonal Sp1 antibodies (Santa Cruz Co., CA, USA). Sp1 and phosphorylated Sp1 were indicated (Sp1 and pSp1).
Detection of apoptotic cells
Chang liver cells on tissue culture plates were cotransfected with 10 mg of pCMV´HBV-X and 10 mg of pCMV´p53wt or 10 mg of pCMV´p53mt249 by the calcium phosphate precipitation method. These transfected cells were harvested by trypsinization and 100 ml of cell suspension (2.0610 6 cells/ ml) were put on coverslips and incubated for 24 h. Transfected cells were treated with either 2.0 ng/ml TNF-a (Calbiochem.), 100 ng/ml IGF-II (Calbiochem.) or both for 16 h. Cells were ®xed with methanol/acetic acid (3:1) and stained with 1 mg/ml Hoechst 33258 for 10 min. Stained cells were observed under a Zeiss Jenaluma¯uorescence microscope. Apoptosis was quantitated by counting condensed Hoechst 33258 stained apoptotic cells.
